Abstract Coronavirus disease 2019 (COVID‐19), which began in Wuhan, China, in
December 2019, has caused a large global pandemic and poses a serious threat to public …

Abstract Angiotensin‐converting enzyme 2 (ACE2) has been established as the functional
host receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus …

Abstract Background In France, the combination hydroxychloroquine (HCQ) and
azithromycin (AZ) is used in the treatment of COVID-19. Methods We retrospectively report …

Introduction SARS-CoV-2 is a novel virus that causes coronavirus disease-19 (COVID-19).
Antiviral and immunomodulatory agents have been proposed as potential treatments …

Background Hydroxychloroquine or chloroquine with or without azithromycin have been
widely promoted to treat coronavirus disease 2019 (COVID-19) following early in vitro …

Background There is no known effective therapy for patients with coronavirus disease 2019
(COVID-19). Initial reports suggesting the potential benefit of hydroxychloroquine …

Severe acute respiratory disease coronavirus 2 (SARS-CoV-2, formerly 2019-nCoV) is a
novel coronavirus that has rapidly disseminated worldwide, causing the coronavirus disease …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral
infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and …

Objectives Clinical studies of chloroquine (CQ) and hydroxychloroquine (HCQ) in COVID-19
disease reported conflicting results. We sought to systematically evaluate the effect of CQ …

The global COVID-19 pandemic has led to a race to find medications that can improve the
prognosis of the disease. Azithromycin, in association with hydroxychloroquine or …